470 related articles for article (PubMed ID: 36762560)
1. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
Lawal OD; Aronow HD; Shobayo F; Hume AL; Taveira TH; Matson KL; Zhang Y; Wen X
Circulation; 2023 Mar; 147(10):782-794. PubMed ID: 36762560
[TBL] [Abstract][Full Text] [Related]
2. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Amin A; Keshishian A; Hines DM; Dina O; Le H; Rosenblatt L; Liu X; Zhang Q; Vo L
Curr Med Res Opin; 2022 Dec; 38(12):2131-2140. PubMed ID: 35993487
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Dawwas GK; Dietrich E; Cuker A; Barnes GD; Leonard CE; Lewis JD
Ann Intern Med; 2021 Jul; 174(7):910-919. PubMed ID: 33780291
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
Lau WCY; Torre CO; Man KKC; Stewart HM; Seager S; Van Zandt M; Reich C; Li J; Brewster J; Lip GYH; Hingorani AD; Wei L; Wong ICK
Ann Intern Med; 2022 Nov; 175(11):1515-1524. PubMed ID: 36315950
[TBL] [Abstract][Full Text] [Related]
5. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
Jansson M; Själander S; Sjögren V; Björck F; Renlund H; Norrving B; Själander A
J Thromb Thrombolysis; 2023 Apr; 55(3):415-425. PubMed ID: 36607464
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
Halvorsen S; Johnsen SP; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):577-587. PubMed ID: 34244745
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Direct Oral Anticoagulants in Thai Patients with Atrial Fibrillation: A Real-World Retrospective Cohort Study.
Srikajornlarp S; Amnueypol M; Vathesatogkit P; Numthavaj P; Ungkanont A; Likittanasombat K; Pattanaprateep O; Angchaisuksiri P; Boonyawat K
Clin Appl Thromb Hemost; 2022; 28():10760296221130058. PubMed ID: 36198021
[TBL] [Abstract][Full Text] [Related]
9. Comparative Safety and Effectiveness of Reduced Doses of Direct Acting Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.
Skjøth F; Larsen TB; Dun AR; Lilja M; Rahman I; Abdelgawwad K; Halvorsen S; Coleman C; Rivera M
Am J Med; 2024 Jun; 137(6):520-528.e13. PubMed ID: 38387539
[TBL] [Abstract][Full Text] [Related]
10. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
[TBL] [Abstract][Full Text] [Related]
12. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
[TBL] [Abstract][Full Text] [Related]
13. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair.
Mentias A; Saad M; Michael M; Nakhla S; Menon V; Harb S; Chaudhury P; Johnston D; Saliba W; Wazni O; Svensson L; Desai MY; Kapadia S
J Am Heart Assoc; 2022 Sep; 11(17):e026666. PubMed ID: 36000413
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation.
Lin KJ; Singer DE; Bykov K; Bessette LG; Mastrorilli JM; Cervone A; Kim DH
JAMA Netw Open; 2023 Mar; 6(3):e234086. PubMed ID: 36976562
[TBL] [Abstract][Full Text] [Related]
15. Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study.
Wetmore JB; Weinhandl ED; Yan H; Reyes JL; Herzog CA; Roetker NS
Am J Kidney Dis; 2022 Nov; 80(5):569-579.e1. PubMed ID: 35469965
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
Lip GYH; Keshishian A; Kang A; Luo X; Atreja N; Zhang Y; Schuler P; Jiang J; Yuce H; Deitelzweig S
J Thromb Thrombolysis; 2022 Jul; 54(1):33-46. PubMed ID: 35579733
[TBL] [Abstract][Full Text] [Related]
17. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
J Manag Care Spec Pharm; 2020 May; 26(5):639-651. PubMed ID: 32347184
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Dhamane AD; Ferri M; Keshishian A; Russ C; Atreja N; Gutierrez C; Emir B; Yuce H; Di Fusco M
Adv Ther; 2023 Mar; 40(3):887-902. PubMed ID: 36527598
[TBL] [Abstract][Full Text] [Related]
20. Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.
Jaksa A; Gibbs L; Kent S; Rowark S; Duffield S; Sharma M; Kincaid L; Ali AK; Patrick AR; Govil P; Jonsson P; Gatto N
BMJ Open; 2022 Oct; 12(10):e064662. PubMed ID: 36253039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]